CCO Slideset

Chronic Myeloid Leukemia

Source: CCO Independent Conference Coverage of the American Society of Hematology 2007 Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Chronic Myeloid Leukemia

Program Director: Roy A. Beveridge, MD

Faculty:

Charles L. Sawyers, MD
Moshe Talpaz, MD

CREDIT INFORMATION

Release Date: March 03, 2008

Expiration Date: March 02, 2009

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: The activity is not currently available for credit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the differences between tyrosine kinase inhibitors and results of recent studies on their use in chronic myeloid leukemia
Discuss the clinical implications of data on the use of tyrosine kinase inhibitors in chronic myeloid leukemia
Relate the role of genetic analyses in determining treatment options for chronic myeloid leukemia

Topics covered include:

Chronic Myeloid Leukemia

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.